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Background: As oral contraceptives (OCs) suppress anti-Müllerian hormone (AMH), and hormonal contraceptives
(HCs), likely, suppress functional ovarian reserve, this study was initiated to determine whether HC affect oocyte
yields.
Methods: We investigated in a retrospective cohort study 43 oocyte donors in 71 in vitro fertilization (IVF) cycles,
evaluating anti-Müllerian hormone (AMH) and oocyte yields as reflections of functional ovarian reserve (OR). In 25
IVF cycles egg donors were on HC within one month prior to IVF, and in 46 cycles they were not. Donors, based on
their HCs, were further subdivided into 12 with less, and 13 with more androgenic progestins.
Results: While the three groups did not differ in age, age at menarche, BMI and AMH, oocyte yields among donors
who utilized estrane- and gonane-derived (higher androgenic) HCs were lower 11.3 (95% CI 8.3 – 14.3) than either
donors using no HCs 16.6 (95% CI 14.7 -18.4) (P < 0.05) or those using anti-androgenic HCs 19.0 (95% CI 12.2-25.8)
(P< 0.01). Significance was maintained after adjustments for the donor age and total FSH dose used in ovulation
induction.
Conclusions: Even in young oocyte donors, high androgenic OC exposure appears to suppress functional ovarian
reserve and oocyte yields. Since OCs are often routinely used in preparation for IVF, such practice may require
reevaluation. Especially in women with diminished ovarian reserve OCs, and especially high androgenic progestin
HCs, should, likely, be avoided.
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AndrogensBackground
Because the response to ovarian stimulation, to a large
degree, depends on choice of stimulation protocols, any
definition of poor response in association with in vitro
fertilization (IVF) has to be considered relative. Poor re-
sponse is, however, universally seen as the production of
fewer than expected oocytes and embryos [1].
While by many considered a standard protocol in IVF,
long agonist stimulations, because of suppressive effects
on ovaries, are often considered inappropriate for poor
responders [2]. Instead, hormonal contraceptives (HCs)* Correspondence: dbarad@thechr.com
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reproduction in any medium, provided the orare regularly utilized in such patients in preparation for
ovulation induction [3,4]. HCs are also used to reduce
ovarian cyst formation [5] and to allow convenient
scheduling of cycle starts [6,7]. Results, utilizing HCs,
have, however, not always been favorable [8-10]. A re-
cent Cochrane review found that pretreatment with
combined oral contraceptives (OCs) led to poorer preg-
nancy outcomes [11].
The primary mode of action for HCs is thought to be
suppression of pituitary gonadotropin secretion, second-
arily leading to suppression of ovarian function [12,13].
So-called combined HCs are combinations of estrogen
(generally ethinyl estradiol, EE) and a variety of proges-
tins. Differences among HCs, therefore, primarily reside
with their progestational agents. Classical HCs havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Progestins in HCs of oocyte donors
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various degrees androgenic [14].
Synthetic progestins interact not only with progester-
one receptors but also with other intranuclear steroid re-
ceptors [15]. Affinities for the various steroid receptors
depend on the molecule from which a given synthetic
progestin is derived [16]. In addition to progestational
activity, steroid derivatives may also have androgenic,
anti-androgenic, estrogenic, glucocorticoid or mineralo-
corticoid activities [16].
Consequently, one also has to conclude that different
OCs, based on progestational content, should affect follicle
maturation differently. Assuming this to be the case, differ-
ent OCs could also be expected to affect functional ovarian
reserve differently and, therefore, potentially oocyte yields.
Progestins may be classified into old progestins
(norethisterone, levonorgestrel, gestodene) and new pro-
gestins (drospirenone, dienogest, trimegestone) [17]. Newer
progestins are designed to be less androgenic. Like spirono-
lactone, from which it derives, drospirenone functions as a
competitive androgen antagonist [18,19]. Dienogest is a 19-
nortestosterone derivative but it differs significantly in
structure from other nortestosterone derivatives [20]. An
OC containing dienogest was recently approved for use in
the United States [21].
AMH is considered a good marker of ovarian aging
[22]. AMH levels generally correlate well with day 2/3
FSH levels [23], and are good predictors of ovarian
response to ovulation induction [24-26].
Suppressive effects of HCs on antral follicles and
AMH levels have been reported. Women with polycystic
ovarian syndrome (PCOS) who for 6 months took OCs,
containing 35 ug of EE and 2 mg of cyproterone acetate,
experienced significant decreases in antral follicles but
no change in anti-Müllerian hormone (AMH) [27].
Cyproterone acetate is anti-androgenic but also sup-
presses gonadotropin secretion [28,29].
Whether OC utilization suppresses AMH has remained
controversial, with some studies supporting such an associ-
ation [30,31], and others disagreeing [32,33]. This diver-
gence suggests that different types of OCs, containing
different progestins, and maybe different utilization length,
could affect results.
Oocyte donors are selected to be healthy young
women, without evidence of infertility and/or abnormal
functional ovarian reserve. They often use OCs or other
HCs. Especially in association with utilization of the so-
called “contraceptive ring” (NuvaRing™, Organon USA),
which contains, and continuously releases, etonogestrel/
ethinyl estradiol, we noted in some of our egg donor ap-
plicants abnormally low age-specific AMH levels. Others
noted diminished numbers of small follicles amongst
women using contraceptive rings in comparison to those
utilizing OCs, containing EE and levonorgestrel [34].Considering all of these observations and reports, we
in here presented study decided to formally investigate
the effects of progestins on follicle maturation by deter-
mining how different HCs affect oocyte yields in young




We retrospectivley reviewed the charts of 46 oocyte do-
nors who underwent 71 IVF cycles. Amongst those, 43
underwent at least one donation cycle, 18 two cycles, 9
three cycles, and one donor 4 cycles. At least six months
elapsed between oocyte donations for donors who con-
tributed more than one cycle to the analysis. Since our
donors are all young women some of them were using
HCs as their method of contraception. The choice of
type of HC was made by the donor’s treating physicians
outside of CHR. If used the HC used was recorded in
each donor’s medical record based on the donor’s self
report. Some donors changed their contraceptive status
between donations and, thus, contributed in more than
one category.
We routinely obtain AMH levels from donor candi-
dates at their initial interview visit with a physician. Use
of any hormonal contraceptives is allowed to continue
until donor candidates are matched with a recipient,
though some chose, on their own, to discontinue earlier.
If more than six months elapse before a donor/recipient
match, donor candidates are rescreened once matched,
and before cycle start.
Study qualifications
Donors qualified for this study if at the time of IVF cycle
start less than 100 days had elapsed from their last
AMH assessment.
Oocyte yields were compared between 46 cycles where
oocyte donors, prior to IVF cycle, were on no HCs, and
25 cycles where donors used HCs within one month of
initiation of treatment. The latter group was further
subdivided into 12 anti-androgenic (11 using contracep-
tives with drospirenone and 1 cyproterone acetate pro-
gestin), and 13 donors with the more androgenic estrane
and gonane-derived progestins. Table 1 lists the various
progestins used by women in this study.
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tion for oocyte donors, including down-regulation with
luteal phase gonadotropin releasing hormone agonist,
and gonadotropin stimulation with 150–300 IU daily of
human menopausal gonadotropin (hMG). Products from
different manufacturers were utilized, depending on pa-
tient preference and/or insurance mandates.
Serum levels of follicle stimulating hormone (FSH)
and estradiol were evaluated on cycle day 2 to 3, using
the Automated Chemo Luminescence System (ACS:
180, Bayer Health Care, Tarrytown, NY). Serum AMH
levels were obtained through a commercially available
assay, which involves an enzymatically amplified two-site
immunoassay, DSL-10-14400 active MIS/AMH ELISA
(Esoterix Endocrinology, Casabasas Hills, CA).Clinical outcomes
Ovarian response was monitored by serial assessments
of serum estradiol and transvaginal ultrasounds of ovar-
ian follicular growth. Oocyte maturation was triggered
with 10,000 IU of human chorionic gonadotrophin
(hCG), when at least three dominant follicles had
attained a size of 18–22 mm. Oocyte retrieval, guided by
transvaginal ultrasound, was performed approximately
34 hours after hCG administration. Oocyte yields were
registered in routine fashion by the embryology staff.Statistical analyses
Baseline characteristics of the groups were tabulated as
means and 95% confidence intervals (CI) of the mean.
Differences at baseline between groups were, when
normally distributed, evaluated by one way analysis of
variance, and by the Mann–Whitney U-test, when non-
normally distributed. A generalized linear model was
used to adjust for the potential confounder of age and
FSH dose, used in ovulation induction, and further
adjusted for repeated cycles. A P-value < 0.05 was con-
sidered significant. All analyses were carried out with
SPSS software for Windows version 19.0 (SPSS Inc.
Chicago, IL.)Ethical approval
The study underwent expedited Institutional Review
Board review, since it involved only analyses of anonym-
ous medical records. At their initial consultation, all of
the center’s patients sign a consent, which allows use of
their anonymous medical records for quality control and
research purposes, as long as their medical records re-
main confidential and their identity protected. Both con-
ditions were met. In addition, all staff with access to
research data at our center, under Federal HIPAA rules,
confirms their obligation to confidentiality in writing.Results and discussion
For the whole study group mean age was 24.2 ± 4.0
years; mean AMH 4.4 ± 2.9 ng/mL; and mean oocyte
yield was 15.6 ± 7.7. Time elapsed between last AMH
and IVF cycle start was 8.9 ± 3.6 weeks.
There was no difference in age, age of menarche, BMI
and AMH among the three groups (Table 2). Mean
AMH was non-significantly higher without HC use but
did not differ significantly between the three groups.
This analysis was further limited by the fact that not all
study subjects had AMH values available for analysis.
Oocyte yields among donors, who utilized more an-
drogenic HCs, like estrane and gonane derived HCs,
were lower 11.3 (95% CI 8.3 – 14.3) than those of either
donors using no HCs at all 16.6 (95% CI 14.7 -18.4) (p <
0.05) or than those using anti-androgenic contraceptives
19.0 (95% CI 12.2-25.8) (p < 0.01) (Figure 1). Comparing
androgenic HCs to the non-androgenic and no HC com-
bined the omnibus test of significance was (p=0.018)
after adjusting for donor age age and total gonadotropin
dosage the significance was (p = 0.03).
In the introduction section of this manuscript we laid
out in detail why, depending on included progestational
agent, HCs should be expected to affect functional ovar-
ian reserve in different ways. Investigating young oocyte
donors, this study presents support for this concept,
suggesting that recent use of HCs affects response of
healthy young women to ovulation induction, resulting
in significantly different oocyte yields, depending on
whether HCs were utilized or not, and depending on
what HCs were used. HC-use before IVF, therefore, quite
apparently reduces the response to ovarian stimulation,
producing lower than expected oocyte numbers. HCs,
therefore, under a recently summarized consensus defin-
ition of poor ovarian response, qualify as inducers of
relatively poor ovarian response to stimulation [1].
Since our center, at most, transfers two embryos in
donor/recipient cycles, a diminution in oocyte yields, as
here reported, likely, will not affect immediate, fresh-
cycle pregnancy rates. Since total available oocytes, and
especially embryos, do, however, reflect cumulative
pregnancy chances, it is reasonable to conclude that any
diminution of oocyte yields will also negatively affect
cumulative pregnancy chances. Especially for recipients,
desirous of more than one child, this may be of
relevance.
The utilization of HCs in women with less favorable
functional ovarian reserve than young oocyte donors, as
represented by many women under standard infertility
treatments with use of autologous oocytes, who may
produce only relatively small oocyte yields, can, however,
also be expected to affect fresh-cycle pregnancy rates
since in such cycles the transfer of larger embryo num-
bers may be indicated.
Table 2 Donor characteristics and oocyte yields in reference to contraceptive use
No contraception Androgenic Anti-androgenic
N Mean 95% CI N Mean 95% CI N Mean 95% CI
Age 46 25.0 24.0–26.1 13 23.5 21.4–25.6 12 24.0 20.3–27.7
Menarche 46 13.2 12.8–13.7 13 12.8 12.1–13.5 12 13.2 12.1–14.2
BMI 46 19.8 19.1–20.5 13 21.1 19..5–22.7 12 19.5 18.4–20.5
AMH 36 4.8 3.8–5.9 12 3.6 2.4–4.9 11 4.0 2.4–5.5
FSH Dose 46 2276 2024–2560 13 2700 1908–3492 12 2639 2392–2885
Oocytes 46 16.6 14.7–18.4* 13 11.3 8.3–14.3 12 19.0 12.2–25.8**
* P < 0.05; ** P < 0.01.
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small data set, still to be considered as preliminary,
nevertheless, warrant a careful reevaluation of current
practice patterns, involving the use of HCs in associ-
ation with IVF.Potential mechanism for findings
As noted before, contraceptive progestins prevent
ovulation through suppression of gonadotropin secretion
and prevention of the LH surge [12,13]. Individual
progestins, however, differ in their ability to suppress
ovulation in animal models in the following declining
order of potency: desogestrel > levonorgestrel > MPA >
norgestimate > norethindrone [35]. Drospirenone alone,
and in combination with ethinyl estradiol, suppressesFigure 1 Oocyte yields of women using androgenic hormonal contrac
contraception were significantly lower than either women using no contraovulation but does not completely suppress follicular
development [36].
We demonstrate in this study that the two anti-
androgenic progestins, drospirenone- and cyproterone
acetate-containing OCs, led to similar oocyte numbers
as in controls, who used no HCs at all, and, therefore, to
significantly larger oocyte yields than in donor who uti-
lized more androgenic HCs.
While the estrogen component may also have a role in
ovarian suppression, significant increases in AMH, antral
follicle counts and ovarian volume values have been
observed after discontinuation of a variety of HCs, unre-
lated to the estrogen dose of HCs [37].
When using OCs, significant follicular growth occurs
during the seven day pill-free interval, while continuous
OC use results in greater suppression of folliculareption. Oocyte yields of women using androgenic hormonal
ception or those using anti-androgenic contraceptives.
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lar growth in association with HCs may extend to antral
and preantral stages of follicle maturation. Such a long-
term effect may also be inferred from sometimes ob-
served delays in resumption of normal cycles following
cessation of HC. In such cases, ovarian biopsies demon-
strate diffuse fibrous stroma, only primordial primary
follicles and atrophic follicular cysts [40].
Considering that our group was the first to offer evi-
dence that the weak androgen, dehydroepiandrosterone
(DHEA) increases the growing follicle pool (i.e., func-
tional ovarian reserve), resulting in higher oocyte yields
and improved embryo quality [41-43], it may, on first
glance, appear contradictory for this group of investiga-
tors to suggest that more androgenic progestins suppress
antral follicle development. A closer look, however,
reveals that such a contradiction may not really exist:
Estrane and gonane progestin/ethinyl estradiol combin-
ation OCs suppress gonadotropins and, consequently, fol-
licular development to a greater degree than drospirenone-
and cyproterone acetate-containing OCs.
In early follicular development androgens work syner-
gistically with FSH [44]. Therefore, utilizing a HC, including
an androgenic progestin, will inhibit gonadotropin support
for the growing follicle but maintain androgen exposure.
Such a constellation may negatively affect follicular devel-
opment, leading to initial androgen-driven follicle growth
but, in the end, to atresia of growing follicles because of
lack of FSH support.
Assuming now a normal oocyte donor without ovarian
PCO phenotype, supplemented with anti-androgenic
HCs, she lacks both, the androgen driven growth of
small growing follicles and the growth support from
FSH. Very small follicles, therefore, will fail to grow, as
in above described constellation, but will, therefore, also
not reach stages of atresia. Assuming discontinuation of
HCs, and reconstitution of FSH support, these small
follicles will, therefore, still have the ability to resume
growth and development, leading to ultimately larger
oocyte yields than with androgenic HCs.
Such a model of required synergism between andro-
gens and FSH at small growing follicle stages to achieve
normal follicle growth and maturation is well described
in animal models [44]. It would suggest that FSH/andro-
gen ratios at these early follicle growth stages may be
predictive of later IVF cycle outcomes in humans.
Limitations
This study’s principal limitation is the relative small
number of study subjects, resulting in the description of
this study as a pilot study in need of further validation.
The potential importance of here first reported findings,
however, warrant publication of these preliminary data
to call attention to the likely suppressive effect of at leastsome HCs on ovarian reserve and encourage further
investigations.
Conclusions
This study, therefore, in summary, suggests that HCs,
containing progestins derived from androgenic estranes
and gonanes, suppress functional ovarian reserve, most
likely via gonadotropin suppression, which interrupts the
normal synergism between androgens and FSH at small
follicle growth stages, in turn impacting oocyte yields.
Since many fertility centers routinely use OCs in prepar-
ation for IVF cycles, such a practice, even in young
women with normal functional reserve, appears to have
negative consequences on oocyte numbers, as here dem-
onstrated in oocyte donors.
An even more profound negative impact from andro-
genic HCs can, however, be expected in women with
diminished functional ovarian reserve. Further investiga-
tions are needed to determine whether they should be
utilized at all. At minimum, the conclusion from this pre-
liminary study should, however, be that androgenic HCs
should, likely, be avoided in women with evidence of low
functional ovarian reserve.
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